Clinical Trials Logo

Filter by:
NCT ID: NCT06273891 Recruiting - Clinical trials for Premature Rupture of Membrane

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

PRACET
Start date: March 8, 2024
Phase: Phase 3
Study type: Interventional

The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. Research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. Currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. Participants diagnosed with PPROM will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. Studying these two drugs will help decide the best care for future patients with PPROM.

NCT ID: NCT06273852 Recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Start date: April 29, 2024
Phase: Early Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.

NCT ID: NCT06273774 Recruiting - Bipolar I Disorder Clinical Trials

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Start date: April 8, 2024
Phase: Phase 1
Study type: Interventional

The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There will be no hypothesis testing in this study.

NCT ID: NCT06273748 Recruiting - Uveitis Clinical Trials

RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age

Start date: February 10, 2022
Phase:
Study type: Observational

Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In Italy, there is no national or regional registry for non-infectious chronic uveitis as per the Prime Ministerial Decree (DPCM) of March 3, 2017 (Identification of surveillance systems and registries for mortality, tumors, and other diseases). However, many clinical centers adopt data recording systems to evaluate the quality of care and to study diseases and outcomes. The Universitary Hospital Meyer Institute Research Hospital (IRCCS) is a national referral center for managing these pediatric cases of non-infectious chronic uveitis, estimated to constitute 95% of all pediatric uveitis cases

NCT ID: NCT06273683 Recruiting - Pregnancy Related Clinical Trials

Comparison of Two Salpingectomy Techniques for Sterilization at the Time of Cesarean Delivery

Start date: March 11, 2024
Phase:
Study type: Observational

One in three women of reproductive age utilize tubal sterilization for contraception, and sterilization is often requested at time of cesarean delivery. Complete salpingectomy for the purpose of permanent sterilization at the time of cesarean birth is increasingly being performed worldwide. A preferred complete salpingectomy technique for the purpose of sterilization at the time of cesarean delivery has not emerged in current practice. The objective is to compare short-term clinical outcomes and cost of salpingectomy using a hand-held bipolar energy instrument with those of traditional suture ligation. This retrospective cohort study will be conducted from 2017-2023 at a single tertiary care hospital. The investigators hypothesize that bipolar energy instrument use will not significantly improve clinical outcomes.

NCT ID: NCT06273618 Recruiting - Knowledge Clinical Trials

iLookOut Micro-learning to Improve Knowledge Retention

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

This project investigates whether a multi-faceted strategy involving iLookOut's evidence-based Core Training plus an innovative follow-up Micro-Learning can promote knowledge retention and change behavior among early childhood professionals (ECPs) with regard to child abuse and its reporting. Additionally, this study will evaluate if non-ECPs experience similar improvements and retention of knowledge and changes in behavior as do ECPs.

NCT ID: NCT06273592 Not yet recruiting - Clinical trials for Erectile Dysfunction

The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.

ERECTION 2
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this study is to determine whether erectile function is differentially impacted by a single plant-based meat meal versus a single animal meat meal in healthy men with normal erectile function.

NCT ID: NCT06273540 Recruiting - Clinical trials for Cocaine Use Disorder

Phase1, STP7 Cocaine Drug-Drug Interaction Study

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age. The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval). The secondary objectives are: - To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine. - To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day. - To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).

NCT ID: NCT06273527 Not yet recruiting - Depression Clinical Trials

Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups. Group 1 will receive a computer-based program that is designed as a cognitive training intervention and Group 2 will receive a similar computer-based exercise that researchers think will be less effective in training thinking skills (also known as a control or sham condition). Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment.

NCT ID: NCT06273462 Not yet recruiting - Chronic Pain Clinical Trials

Palmitoylethanolamide for Chronic Inflammatory Pain Conditions

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo. Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.